Abeome Corporation is a privately-held biotechnology company leveraging its proprietary technology to discover therapeutic and diagnostic monoclonal antibodies (mAbs). Abeome makes custom mAbs under both fee-for-service and co-development agreements to serve academic and corporate partners around the world.
Internally, Abeome has rapidly advanced the use of the technology to discover potential therapeutic and diagnostic mAbs for ovarian cancer in collaboration with Fox Chase Cancer Center. From a large library of antibodies generated from whole-cell immunization, Abeome screened down to 34 of the most promising candidates and tested each on tissue microarrays from human patients. Many of these antibodies are highly disease-specific, and will be used in tumor regression studies in mice.
Abeome has developed proprietary, patented mAb technology that dramatically reduces cycle time and boosts yields of positives for each antigen target. By doing so, the Company is more discriminating in selecting those mAbs with the most optimal characteristics to move forward in therapeutic and diagnostic development projects.
The technology is based on the innovative research of the Abeome's scientific founder, Dr. Richard Meagher, Professor of Genetics at the University of Georgia. In addition to the scientific founder and CSO, the Board of Directors and Scientific Advisory Board are steeped in biotech and entrepreneurial experts including original scientists at both Amgen and Genentech, two of the largest biotech companies in the world.
Together, this strong team of individuals collaborates with Fox Chase Cancer Center, Cato Research (CRO), and a variety of large and small biotechnology and pharmaceutical companies to bring Abeome's technological advancements to the scientific community.
For additional information about Abeome's technology, click here.
Internally, Abeome has rapidly advanced the use of the technology to discover potential therapeutic and diagnostic mAbs for ovarian cancer in collaboration with Fox Chase Cancer Center. From a large library of antibodies generated from whole-cell immunization, Abeome screened down to 34 of the most promising candidates and tested each on tissue microarrays from human patients. Many of these antibodies are highly disease-specific, and will be used in tumor regression studies in mice.
Abeome has developed proprietary, patented mAb technology that dramatically reduces cycle time and boosts yields of positives for each antigen target. By doing so, the Company is more discriminating in selecting those mAbs with the most optimal characteristics to move forward in therapeutic and diagnostic development projects.
The technology is based on the innovative research of the Abeome's scientific founder, Dr. Richard Meagher, Professor of Genetics at the University of Georgia. In addition to the scientific founder and CSO, the Board of Directors and Scientific Advisory Board are steeped in biotech and entrepreneurial experts including original scientists at both Amgen and Genentech, two of the largest biotech companies in the world.
Together, this strong team of individuals collaborates with Fox Chase Cancer Center, Cato Research (CRO), and a variety of large and small biotechnology and pharmaceutical companies to bring Abeome's technological advancements to the scientific community.
For additional information about Abeome's technology, click here.
